Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from MaxCyte ( (MXCT) ) is now available.
MaxCyte, Inc. has announced the issuance of 19,904 shares of common stock in response to the exercise of share options and vesting of restricted stock units, bringing the total issued stock capital to 105,711,093 shares. This update allows shareholders to calculate their interest changes in the company’s stock capital, reflecting the company’s ongoing developments in the cell engineering sector.
More about MaxCyte
MaxCyte, Inc. is a leading company in the cell-engineering industry, focused on providing platform technologies that advance the discovery, development, and commercialization of next-generation cell therapeutics. Their ExPERT™ platform, based on Flow Electroporation® technology, supports the cell therapy market from discovery to commercialization. MaxCyte offers four instruments, a range of proprietary processing assemblies, and software protocols, all backed by a global intellectual property portfolio.
Average Trading Volume: 44,266
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £350.5M
For an in-depth examination of MXCT stock, go to TipRanks’ Stock Analysis page.
